On the other hand, GBM cells have been demonstrated to withstand mTOR inhibition by activating glutamine metabolism via glutaminase (GLS) and combined mTOR and GLS inhibition results in synergistic tumor growth inhibition in a GBM preclinical setting [105]. This evidence concerns the gene GLS and neoplasm.